CN101128196B - 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合 - Google Patents

用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合 Download PDF

Info

Publication number
CN101128196B
CN101128196B CN2006800061530A CN200680006153A CN101128196B CN 101128196 B CN101128196 B CN 101128196B CN 2006800061530 A CN2006800061530 A CN 2006800061530A CN 200680006153 A CN200680006153 A CN 200680006153A CN 101128196 B CN101128196 B CN 101128196B
Authority
CN
China
Prior art keywords
montelukast
medicament
copd
dose
glycopyrronium bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800061530A
Other languages
English (en)
Chinese (zh)
Other versions
CN101128196A (zh
Inventor
J·毛斯
B·菲尔尼斯
T·霍夫曼
M·魏因加特
I·采兰伊
P·J·克诺塔
U·蒙策尔
U·佩措尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Meda Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma GmbH and Co KG filed Critical Meda Pharma GmbH and Co KG
Publication of CN101128196A publication Critical patent/CN101128196A/zh
Application granted granted Critical
Publication of CN101128196B publication Critical patent/CN101128196B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2006800061530A 2005-03-16 2006-03-10 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合 Expired - Fee Related CN101128196B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66191805P 2005-03-16 2005-03-16
US60/661,918 2005-03-16
PCT/EP2006/002247 WO2006097250A1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases

Publications (2)

Publication Number Publication Date
CN101128196A CN101128196A (zh) 2008-02-20
CN101128196B true CN101128196B (zh) 2013-01-02

Family

ID=36570797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800061530A Expired - Fee Related CN101128196B (zh) 2005-03-16 2006-03-10 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合

Country Status (18)

Country Link
US (1) US8268864B2 (enExample)
EP (1) EP1863476B1 (enExample)
JP (1) JP4991693B2 (enExample)
CN (1) CN101128196B (enExample)
AU (1) AU2006224842B2 (enExample)
CA (1) CA2595791C (enExample)
CY (1) CY1117571T1 (enExample)
DK (1) DK1863476T3 (enExample)
ES (1) ES2570332T3 (enExample)
HR (1) HRP20160373T1 (enExample)
HU (1) HUE027076T2 (enExample)
MX (1) MX2007011273A (enExample)
NO (1) NO340405B1 (enExample)
NZ (1) NZ560206A (enExample)
PL (1) PL1863476T3 (enExample)
RU (1) RU2420285C2 (enExample)
SI (1) SI1863476T1 (enExample)
WO (1) WO2006097250A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
AU2004261610B2 (en) * 2003-07-28 2010-05-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators
US7737145B2 (en) 2005-12-29 2010-06-15 Estrellita Pharmaceuticals, Llc Diamine derivatives as inhibitors of leukotriene A4 hydrolase
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
US8618160B2 (en) * 2007-10-18 2013-12-31 Rose U Topical glycopyrrolate formulations
KR20100072295A (ko) * 2007-10-25 2010-06-30 머크 프로스트 캐나다 리미티드 병용 요법
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US9378456B2 (en) * 2012-11-19 2016-06-28 Microsoft Technology Licensing, Llc Task completion
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
MX2016008953A (es) * 2014-01-10 2017-02-02 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
KR20210114962A (ko) * 2019-01-10 2021-09-24 장인 무코케어 파마슈티컬 컴퍼니 리미티드 류코트리엔 수용체 길항제를 함유하는 신규 제제
BR112022015199A2 (pt) * 2020-02-03 2022-10-11 Taro Pharma Ind Formulações tópicas de montelucaste
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
CN1575163A (zh) * 2001-10-26 2005-02-02 麦克弗罗斯特(加拿大)公司 孟鲁司特颗粒制剂

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0435038A (ja) * 1990-05-31 1992-02-05 Oki Electric Ind Co Ltd 半導体素子及びその製造方法
KR100331255B1 (ko) * 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
DE59709927D1 (de) * 1996-11-11 2003-05-28 Noe Christian Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
WO1999062720A1 (fr) * 1998-05-29 1999-12-09 Citizen Watch Co., Ltd. Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
YU33103A (sh) * 2000-10-31 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Formulacija rastvora za inhalaciju sa soli tiotropijuma
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
DE50211045D1 (de) 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
MXPA03010791A (es) 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
CZ20033150A3 (cs) 2001-05-25 2004-06-16 Pfizer Inc. Inhibitor PDE4 a anticholinergní činidlo v kombinaci pro léčbu obstruktivních chorob dýchacích cest
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE60216242T2 (de) * 2002-06-06 2007-05-24 Chiesi Farmaceutici S.P.A. Lösung von Wirkstoffen in HFA-Treibgasen mittels Emulsionen
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
WO2004023984A2 (en) * 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
WO2004054556A1 (en) * 2002-12-13 2004-07-01 Adagit Pharmaceutical porous particles
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
SI1610787T1 (sl) * 2003-03-28 2008-06-30 Nycomed Gmbh Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni
WO2005055999A1 (ja) 2003-12-08 2005-06-23 Nippon Shinyaku Co., Ltd. 抗コリン作用剤
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
CN1575163A (zh) * 2001-10-26 2005-02-02 麦克弗罗斯特(加拿大)公司 孟鲁司特颗粒制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G. Tzelepis,et al.Comparison of nebulized glycopyrrolate and metaproterenol inchronic obstructive pulmonary disease.European Respiatory Journal 9.1996,(9),100-103.
G. Tzelepis,et al.Comparison of nebulized glycopyrrolate and metaproterenol inchronic obstructive pulmonary disease.European Respiatory Journal 9.1996,(9),100-103. *
Pinar Celik et al.Short-term effects of montelukast in stable patients withmoderate to severe COPD.Respiratory Medicine 99.2004,(99),444-450.
Pinar Celik et al.Short-term effects of montelukast in stable patients withmoderate to severe COPD.Respiratory Medicine 99.2004,(99),444-450. *

Also Published As

Publication number Publication date
HRP20160373T1 (hr) 2016-05-06
AU2006224842B2 (en) 2011-09-29
CA2595791C (en) 2013-10-08
ES2570332T3 (es) 2016-05-17
HK1114013A1 (en) 2008-10-24
US20060211729A1 (en) 2006-09-21
CN101128196A (zh) 2008-02-20
SI1863476T1 (sl) 2016-05-31
EP1863476B1 (en) 2016-02-03
MX2007011273A (es) 2007-11-08
JP4991693B2 (ja) 2012-08-01
NO20075287L (no) 2007-12-05
PL1863476T3 (pl) 2016-07-29
HUE027076T2 (en) 2016-08-29
NZ560206A (en) 2009-09-25
RU2420285C2 (ru) 2011-06-10
CA2595791A1 (en) 2006-09-21
DK1863476T3 (en) 2016-05-17
NO340405B1 (no) 2017-04-18
AU2006224842A1 (en) 2006-09-21
JP2008533072A (ja) 2008-08-21
CY1117571T1 (el) 2017-04-26
EP1863476A1 (en) 2007-12-12
RU2007138270A (ru) 2009-04-27
WO2006097250A1 (en) 2006-09-21
US8268864B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
CN101128196B (zh) 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
RU2404771C2 (ru) Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты
JP2018168172A (ja) ロフルミラストｎ−酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法
AU2005247104B2 (en) Combinations comprising antimuscarinic agents and beta-adrenergic agonists
CN100512813C (zh) 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
JP2022520990A (ja) 呼吸器疾患の治療の方法
UA119773C2 (uk) Комбінації тіотропію броміду, формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
DK2696871T3 (en) ACLIDINIUM FOR USE TO IMPROVE SLEEP QUALITY OF RESPIRATORY PATIENTS
US20050222102A1 (en) Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroids
HK1114013B (en) The combination of anticholinergics and leukotriene receptor antagonists for the treatment of repiratory diseases
HK1097757A (en) Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
KR20070018104A (ko) 항무스카린제 및 베타-아드레날린 작용제를 포함하는조합물
MXPA06008935A (en) Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
NZ707754A (en) Combination of glycopyrrolate and a beta2 -agonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114013

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1114013

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130102